Why IBD 50’s Alnylam Just Reversed Its 50% Gain — And BridgeBio Surged
Investor's Business DailyAlnylam stock tumbled Friday after the company’s Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.
The post Why IBD 50's Alnylam Just Reversed Its 50% Gain — And BridgeBio Surged appeared first on Investor's Busi…